← All organizations
Highest phase reached
Phase 4
First clinical trial
Aug 10, 2017First marketed drug
Jan 7, 2022First NDA
Jan 7, 2022Last known activity
Nov 30, 2025
Timeline
2010s
- Jun 1, 2017
Idorsia Pharmaceuticals Ltd.— Founded
2020s
- Jan 7, 2022
daridorexant— Marketing Organization
- Jan 7, 2022
daridorexant— NDA Organization
- Jan 7, 2022
daridorexant— NDA Secondary Org
Drugs by trial phase (40 distinct, 76 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (6 own, 0 via acquisition)
Phase 1 (28 own, 0 via acquisition)
Indications
Studied for
- Apnea
- Colorectal Neoplasms
- Coronary Artery Disease
- Coronary Disease
- Epilepsy
- Epilepsy, Reflex
- Fabry Disease
- Hemorrhage
- Hypertension
- Infarction
- Kidney Diseases
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lupus Erythematosus, Systemic
- Myocardial Infarction
- Myocardial Ischemia
- Nasal Polyps
- Nasopharyngeal Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Sleep Apnea, Obstructive
- Sleep Apnea Syndromes
- Sleep Initiation and Maintenance Disorders
- Subarachnoid Hemorrhage
Marketed drugs (2)
Recent trials (50)
- NCT06816433CollaboratorPhase 2Nov 30, 2025
- NCT06799884Lead sponsorPhase 1Jan 18, 2025
- NCT06799884OfficialPhase 1Jan 18, 2025
- NCT06475742Lead sponsorPhase 3Jul 30, 2024
- NCT06475742OfficialPhase 3Jul 30, 2024
- NCT05948553CollaboratorPhase 2Nov 2, 2023
- NCT05948540CollaboratorPhase 2Nov 2, 2023
- NCT05948579CollaboratorPhase 2Aug 31, 2023
- NCT05924425CollaboratorPhase 4Jul 1, 2023
- NCT05672576Study directorPhase 3Jun 26, 2023
- NCT05672576Lead sponsorPhase 3Jun 26, 2023
- NCT05877222Study directorPhase 1Jun 23, 2023
- NCT05877222Lead sponsorPhase 1Jun 23, 2023
- NCT05702177Lead sponsorPhase 1Jan 5, 2023
- NCT05702177Study directorPhase 1Jan 5, 2023
Details
- Founded
- Allschwil, CH Jun 1, 2017
- First NDA
- Jan 7, 2022
- Last known activity
- Nov 30, 2025
Notes
Spun out from Actelion